Lazard Asset Management LLC Sells 51,337 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)

Lazard Asset Management LLC lowered its position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 90.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,656 shares of the company’s stock after selling 51,337 shares during the period. Lazard Asset Management LLC’s holdings in GoodRx were worth $26,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of GDRX. Vanguard Group Inc. raised its holdings in GoodRx by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 8,373,039 shares of the company’s stock valued at $38,935,000 after buying an additional 460,753 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of GoodRx by 22.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company’s stock worth $9,264,000 after purchasing an additional 369,553 shares during the last quarter. Clearbridge Investments LLC acquired a new stake in GoodRx in the fourth quarter valued at $5,863,000. Connor Clark & Lunn Investment Management Ltd. raised its position in GoodRx by 38.7% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,228,836 shares of the company’s stock worth $5,714,000 after purchasing an additional 342,781 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of GoodRx by 9.1% in the 4th quarter. Geode Capital Management LLC now owns 1,071,761 shares of the company’s stock valued at $4,986,000 after buying an additional 89,032 shares during the last quarter. 63.77% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

GDRX has been the subject of several analyst reports. The Goldman Sachs Group lowered their price target on shares of GoodRx from $6.00 to $5.00 and set a “neutral” rating for the company in a report on Friday, May 9th. UBS Group cut their price target on shares of GoodRx from $6.00 to $5.25 and set a “neutral” rating on the stock in a research report on Tuesday, May 13th. Wells Fargo & Company dropped their price objective on GoodRx from $8.00 to $7.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 29th. Finally, Truist Financial decreased their target price on GoodRx from $6.50 to $5.50 and set a “hold” rating for the company in a research note on Thursday, April 10th. Five analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $6.55.

GoodRx Trading Down 2.1%

Shares of GDRX stock opened at $3.74 on Tuesday. The company has a 50 day moving average of $4.36 and a 200-day moving average of $4.57. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx Holdings, Inc. has a 12-month low of $3.68 and a 12-month high of $9.26. The firm has a market cap of $1.34 billion, a P/E ratio of -124.67, a PEG ratio of 2.46 and a beta of 1.24.

GoodRx (NASDAQ:GDRX) last issued its earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.05. The firm had revenue of $202.97 million for the quarter, compared to analyst estimates of $202.25 million. GoodRx had a positive return on equity of 5.35% and a negative net margin of 2.05%. The business’s revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.08 earnings per share. Sell-side analysts anticipate that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.